Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
The Japan Pharmaceutical Manufacturers Association (JPMA) will launch a new project in FY2026 to address nitrosamine risks in APIs used in clinical trials, with plans to publish standardized guidelines as early as next fiscal year. The move — which forms…
To read the full story
ORGANIZATION
- Digital Health Group Eager to Gain Full Seat at Chuikyo Table
September 25, 2026
- Japan Wholesalers’ Profit Margin Worsens to 1.04% as Costs Rise
September 25, 2026
- Think Tank Advocates Drug Price Hikes above Existing Levels to Reflect Inflation
September 25, 2026
- Keidanren Calls for English Drug Filings to Be Opened to Japan-Based Firms
September 16, 2026
- JPWA Disbands Kumamoto Quake Disaster Response HQ
September 14, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…